Cardiometabolic Health & Insulin Resistance
Diabetes, obesity, insulin resistance, hypertension, dyslipidaemia and abdominal adiposity frequently coexist, creating a network of risk factors that shapes cardiovascular outcomes. IMACH places cardiometabolic health at the centre of its scientific vision.
Treating the network, not just the nodes.
Cardiometabolic health represents the intersection of metabolic disorders and cardiovascular disease. Effective prevention and management require an integrated understanding of multiple interconnected conditions rather than isolated disease management.
Insulin resistance is a key biological pathway linking these conditions. It influences metabolic dysfunction across the liver, skeletal muscle, adipose tissue and the cardiovascular system, and frequently precedes the diagnosis of diabetes or cardiovascular disease by many years.
Metabolic syndrome — the clustering of abdominal obesity, insulin resistance, raised blood pressure, elevated triglycerides and impaired glucose regulation — significantly increases the risk of Type 2 diabetes and cardiovascular disease. IMACH aims to advance understanding of the mechanisms connecting these conditions and to promote comprehensive cardiovascular risk assessment and reduction.
Key areas of scientific focus
Risk & mechanisms
- Cardiometabolic risk assessment and stratification
- Pathophysiology of insulin resistance
- Metabolic syndrome and diagnostic criteria
- Visceral adiposity and ectopic fat accumulation
- Adipokines and metabolic inflammation
- Emerging biomarkers and cardiovascular imaging
Clinical management
- Diabetes-associated cardiovascular risk
- Obesity and cardiovascular complications
- Role of SGLT2 inhibitors and GLP-1 receptor agonists
- Integrated management of blood pressure and lipids
- Heart failure prevention in metabolic disorders
- Pharmacological approaches to metabolic risk
Early risk & prevention
- Prediabetes and early metabolic dysfunction
- Insulin resistance in PMOS
- Hepatic insulin resistance and MASLD
- Metabolic risk in younger adults
- Lifestyle and dietary interventions
- Risk prediction and preventive interventions
Clinical challenges we address
Risk factors managed in silos
Blood pressure, lipids and glucose are often treated by different specialists without a unified risk plan.
Under-recognised insulin resistance
Early metabolic dysfunction frequently goes undetected until disease is established.
Interpreting outcome trials
Translating cardiovascular outcome trial evidence into individual decisions is complex.
Young adults at risk
Metabolic risk is rising in younger people who rarely undergo assessment.
Residual risk
Many patients remain at high risk despite treatment of individual factors.
Lifestyle implementation
Sustained behavioural change remains the hardest intervention to deliver.
Translating evidence into everyday care
IMACH emphasises the interpretation of clinical evidence, implementation of contemporary guidelines and risk-based treatment decisions, including the integration of newer cardiometabolic therapies.
A structured approach helps clinicians move from identifying risk to reducing it.
| Care stage | Focus for clinicians |
|---|---|
| Identify | Screen for central obesity, raised blood pressure, dyslipidaemia, dysglycaemia and family history. |
| Assess | Calculate global cardiometabolic risk; consider biomarkers and imaging where appropriate. |
| Intervene | Lifestyle and nutrition therapy as foundation; pharmacotherapy matched to risk and organ protection. |
| Integrate | Coordinate blood pressure, lipid, glucose and weight management in one plan. |
| Follow up | Reassess risk over time and address residual risk. |
IMACH programmes in this area
Cardiometabolic risk clinics (training)
Structured frameworks for global risk assessment in practice.
Outcome-trial update sessions
Expert interpretation of major cardiovascular outcome trials.
Insulin resistance masterclass
Mechanisms, assessment and early intervention.
Joint cardiology–diabetology symposia
Cross-specialty discussions on integrated care.
Young-adult metabolic risk programme
Awareness and screening in younger populations.
Case conferences
Complex patients with multiple coexisting risk factors.
Who this area brings together
Cardiometabolic care requires engagement between specialties that traditionally work separately. IMACH encourages joint learning and shared care pathways.
Questions we explore
- How can global cardiometabolic risk be assessed simply and reliably in busy practice?
- Which patients benefit most from organ-protective therapies?
- How should insulin resistance be identified before diabetes develops?
- What role do novel biomarkers and imaging play in risk stratification?
- How can lifestyle interventions be delivered at scale and sustained?
Frequently asked questions
What is the difference between cardiometabolic health and metabolic syndrome?
Metabolic syndrome is a defined cluster of risk factors. Cardiometabolic health is the broader field that addresses how metabolic and cardiovascular conditions interact, including but not limited to metabolic syndrome.
Why combine these topics?
Because insulin resistance and metabolic syndrome are the shared biological foundation of most cardiometabolic disease. Addressing them together supports earlier and more effective prevention.
Is this area relevant to primary care?
Very much so. Early identification of cardiometabolic risk largely happens in primary care settings.
This page is intended for healthcare professionals and is educational in nature. It does not constitute medical advice or treatment recommendations for individual patients. Clinical decisions should follow current guidelines, local regulations and individual patient assessment.
Contribute to cardiometabolic health at IMACH.
Join as a member, faculty or research collaborator in this therapy area.